KliWES 2.0 – Klimawandel und Wasserhaushalt: Methodikoptimierung der Wasserhaushaltsmodellierung, Fortschreibung von Modelleingangsdaten, sachsenweite Wasserhaushaltsmodellierung für Ist-Zustand und Szenarien sowie Weiterentwicklung der KliWES-Internetanwendung im Wasserhaushaltsportal Sachsen

Die Schriftenreihe informiert über die Fortschreibung des Projektes „Klimawandel und Wasserhaushalt in Sachsen“ (KlIWES-2.0) mit einem weiterentwickelten ARCEGMO- Modell- Konzept. Zunächst erfolgte eine Neuberechnung des IST- Wasserhaushaltes bis 2015. Ergänzend wurden mit acht ausgewählten WEREX-VI- Klima- Realisierungen künftige Wasserhaushalts- Entwicklungen (bis 2100) modelliert. Die Ergebnisse zeigen überwiegend ein weiter abnehmende Abfluss- Dargebots- Entwicklung in den Gewässereinzugsgebieten. Über das neue Anwendungs- Tool „KliWES-2.0“ sind die Ergebnisse im „Wasserhaushaltsportal Sachsen“ für einen breiten Nutzerkreis auch webbasiert verfügbar. Redaktionsschluss: 10.06.202

Subalterne Vorstellungen von Bildung

Aytekin V, Boger JM-A. Subalterne Vorstellungen von Bildung. In: Geuenich S, Krenz-Dewe D, Niggemann J, Pfützner R, Witek K, eds. Wozu brauchen wir das? – Bildungsphilosophie und pädagogische Praxis. Münster: Westfälisches Dampfboot.; 2016

KliWES 2.0 – Klimawandel und Wasserhaushalt: Methodikoptimierung der Wasserhaushaltsmodellierung, Fortschreibung von Modelleingangsdaten, sachsenweite Wasserhaushaltsmodellierung für Ist-Zustand und Szenarien sowie Weiterentwicklung der KliWES-Internetanwendung im Wasserhaushaltsportal Sachsen

Die Schriftenreihe informiert über die Fortschreibung des Projektes „Klimawandel und Wasserhaushalt in Sachsen“ (KlIWES-2.0) mit einem weiterentwickelten ARCEGMO- Modell- Konzept. Zunächst erfolgte eine Neuberechnung des IST- Wasserhaushaltes bis 2015. Ergänzend wurden mit acht ausgewählten WEREX-VI- Klima- Realisierungen künftige Wasserhaushalts- Entwicklungen (bis 2100) modelliert. Die Ergebnisse zeigen überwiegend ein weiter abnehmende Abfluss- Dargebots- Entwicklung in den Gewässereinzugsgebieten. Über das neue Anwendungs- Tool „KliWES-2.0“ sind die Ergebnisse im „Wasserhaushaltsportal Sachsen“ für einen breiten Nutzerkreis auch webbasiert verfügbar. Redaktionsschluss: 10.06.202

Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults

Aims: Contradictory reports exist regarding the influence of the exon 3 deleted (d3)/full-length (fl) growth hormone receptor (GHR) polymorphism on responsiveness to recombinant human growth-hormone therapy in idiopathic short stature, small for gestational age and GH-deficient children, Turner syndrome patients and GH-deficient adults. In some of these studies, the d3 allele was associated with increased responsiveness to GH. The aim of this study was to test this association in a group of GH-deficient adult patients receiving recombinant GH treatment. Materials &amp; methods: Patients were derived from the prospective German Pfizer International Metabolic Study (KIMS) Pharmacogenetics Study. The GHRd3/fl polymorphism was determined in 133 German adult patients (66 men and 67 women; mean age: 45.4 years ± 13.1 standard deviation; majority Caucasian) with a GH-deficiency of different origin. Patients received GH treatment for 12 months with a finished dose-titration of GH and standardized insulin-like growth factor (IGF)-1 measurements in one central laboratory. GH dose after 1 year of treatment, IGF-1 serum concentrations, IGF-1 standard deviation score (SDS) values and anthropometric data were analyzed by GHRd3/fl genotypes. Results: After 1 year of GH treatment, the individually required GH dose was significantly lower in GH-deficient patients carrying one or two d3 alleles, compared with patients with the full-length receptor (p = 0.04). Genotype groups (d3-allele carriers vs noncarriers) showed no significant differences in IGF-1 serum concentrations (p = 0.51), IGF-1 SDS (p = 0.36) nor in gender (p = 0.53), age (p = 0.28), weight (p = 0.13), height (p = 0.53) or BMI (p = 0.15). Conclusion: The d3-allele carriers required approximately 25% less exogenous GH compared with the homozygous fl-allele carriers, which may express an increased responsiveness to exogenous GH. Variability of the individually required GH dose in adult GH-deficient patients may therefore be partly due to the GHRd3/fl polymorphism. Further studies are required to confirm these results.</p

Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults

Aims: Contradictory reports exist regarding the influence of the exon 3 deleted (d3)/full-length (fl) growth hormone receptor (GHR) polymorphism on responsiveness to recombinant human growth-hormone therapy in idiopathic short stature, small for gestational age and GH-deficient children, Turner syndrome patients and GH-deficient adults. In some of these studies, the d3 allele was associated with increased responsiveness to GH. The aim of this study was to test this association in a group of GH-deficient adult patients receiving recombinant GH treatment. Materials &amp; methods: Patients were derived from the prospective German Pfizer International Metabolic Study (KIMS) Pharmacogenetics Study. The GHRd3/fl polymorphism was determined in 133 German adult patients (66 men and 67 women; mean age: 45.4 years ± 13.1 standard deviation; majority Caucasian) with a GH-deficiency of different origin. Patients received GH treatment for 12 months with a finished dose-titration of GH and standardized insulin-like growth factor (IGF)-1 measurements in one central laboratory. GH dose after 1 year of treatment, IGF-1 serum concentrations, IGF-1 standard deviation score (SDS) values and anthropometric data were analyzed by GHRd3/fl genotypes. Results: After 1 year of GH treatment, the individually required GH dose was significantly lower in GH-deficient patients carrying one or two d3 alleles, compared with patients with the full-length receptor (p = 0.04). Genotype groups (d3-allele carriers vs noncarriers) showed no significant differences in IGF-1 serum concentrations (p = 0.51), IGF-1 SDS (p = 0.36) nor in gender (p = 0.53), age (p = 0.28), weight (p = 0.13), height (p = 0.53) or BMI (p = 0.15). Conclusion: The d3-allele carriers required approximately 25% less exogenous GH compared with the homozygous fl-allele carriers, which may express an increased responsiveness to exogenous GH. Variability of the individually required GH dose in adult GH-deficient patients may therefore be partly due to the GHRd3/fl polymorphism. Further studies are required to confirm these results.</p

KliWES 2.0 – Klimawandel und Wasserhaushalt: Methodikoptimierung der Wasserhaushaltsmodellierung, Fortschreibung von Modelleingangsdaten, sachsenweite Wasserhaushaltsmodellierung für Ist-Zustand und Szenarien sowie Weiterentwicklung der KliWES-Internetanwendung im Wasserhaushaltsportal Sachsen

Die Schriftenreihe informiert über die Fortschreibung des Projektes „Klimawandel und Wasserhaushalt in Sachsen“ (KlIWES-2.0) mit einem weiterentwickelten ARCEGMO- Modell- Konzept. Zunächst erfolgte eine Neuberechnung des IST- Wasserhaushaltes bis 2015. Ergänzend wurden mit acht ausgewählten WEREX-VI- Klima- Realisierungen künftige Wasserhaushalts- Entwicklungen (bis 2100) modelliert. Die Ergebnisse zeigen überwiegend ein weiter abnehmende Abfluss- Dargebots- Entwicklung in den Gewässereinzugsgebieten. Über das neue Anwendungs- Tool „KliWES-2.0“ sind die Ergebnisse im „Wasserhaushaltsportal Sachsen“ für einen breiten Nutzerkreis auch webbasiert verfügbar. Redaktionsschluss: 10.06.202

Growth hormone dose in growth hormone-deficient adults is not associated with IGF-1 gene polymorphisms

Aims: Several SNPs and a microsatellite cytosine-adenine repeat promoter polymorphisms of the IGF-1 gene have been reported to be associated with circulating IGF-1 serum concentrations. Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (GH) treatment, resulting in different individually required GH-doses in GH-defecient patients. The aim of this study was to test if the IGF-1 gene polymorphisms are associated with the GH-dose of GH-defecient adults. Materials &amp; methods: A total of nine SNPs, five addtionally selected SNPs and a cytosine-adenine repeat polymorphism were determined in 133 German adult patients (66 men, 67 women; mean age 45.4 years ± 13.1 stamdard deviation; majority Caucasian) with GH-deficiency (GHD) of different origin, derived from the prospective Pfizer International Metabolic Study (KIMS) Pharmacogenetics Study. Patients received GH-treatment for 12 months with finished dose-titration of GH and centralized IGF-1 measurements. GH-dose after 1 year of treatment, IGF-1 concentrations, IGF-1-standard deviation score (SDS), the IGF-1:GH ratio and anthropometric data were analyzed by genotyped. Results: Except for rs1019731, which showed a significant difference of IGF-1-SDS by genotypes (p=0.02), all polymorphisms showed no associations with the GH-doses, IGF-1 concentrations, IGF-1-SDS and IGF-1:GH ration after adjusting for the confounding variables gender, age and BMI. Conclusion: IGF-1 gene polymorphisms were not associated with the responsiveness to exogenous GH in GHD. Therefore, genetic variations of the IGF-1 genen seem not to be major influencing factors of the GH-IGF-axis causing variable response to exogenous GH-treatment.</p

Growth hormone dose in growth hormone-deficient adults is not associated with IGF-1 gene polymorphisms

Aims: Several SNPs and a microsatellite cytosine-adenine repeat promoter polymorphisms of the IGF-1 gene have been reported to be associated with circulating IGF-1 serum concentrations. Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (GH) treatment, resulting in different individually required GH-doses in GH-defecient patients. The aim of this study was to test if the IGF-1 gene polymorphisms are associated with the GH-dose of GH-defecient adults. Materials &amp; methods: A total of nine SNPs, five addtionally selected SNPs and a cytosine-adenine repeat polymorphism were determined in 133 German adult patients (66 men, 67 women; mean age 45.4 years ± 13.1 stamdard deviation; majority Caucasian) with GH-deficiency (GHD) of different origin, derived from the prospective Pfizer International Metabolic Study (KIMS) Pharmacogenetics Study. Patients received GH-treatment for 12 months with finished dose-titration of GH and centralized IGF-1 measurements. GH-dose after 1 year of treatment, IGF-1 concentrations, IGF-1-standard deviation score (SDS), the IGF-1:GH ratio and anthropometric data were analyzed by genotyped. Results: Except for rs1019731, which showed a significant difference of IGF-1-SDS by genotypes (p=0.02), all polymorphisms showed no associations with the GH-doses, IGF-1 concentrations, IGF-1-SDS and IGF-1:GH ration after adjusting for the confounding variables gender, age and BMI. Conclusion: IGF-1 gene polymorphisms were not associated with the responsiveness to exogenous GH in GHD. Therefore, genetic variations of the IGF-1 genen seem not to be major influencing factors of the GH-IGF-axis causing variable response to exogenous GH-treatment.</p

Growth hormone dose in growth hormone-deficient adults is not associated with IGF-1 gene polymorphisms

Aims: Several SNPs and a microsatellite cytosine-adenine repeat promoter polymorphisms of the IGF-1 gene have been reported to be associated with circulating IGF-1 serum concentrations. Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (GH) treatment, resulting in different individually required GH-doses in GH-defecient patients. The aim of this study was to test if the IGF-1 gene polymorphisms are associated with the GH-dose of GH-defecient adults. Materials & methods: A total of nine SNPs, five addtionally selected SNPs and a cytosine-adenine repeat polymorphism were determined in 133 German adult patients (66 men, 67 women; mean age 45.4 years ± 13.1 stamdard deviation; majority Caucasian) with GH-deficiency (GHD) of different origin, derived from the prospective Pfizer International Metabolic Study (KIMS) Pharmacogenetics Study. Patients received GH-treatment for 12 months with finished dose-titration of GH and centralized IGF-1 measurements. GH-dose after 1 year of treatment, IGF-1 concentrations, IGF-1-standard deviation score (SDS), the IGF-1:GH ratio and anthropometric data were analyzed by genotyped. Results: Except for rs1019731, which showed a significant difference of IGF-1-SDS by genotypes (p=0.02), all polymorphisms showed no associations with the GH-doses, IGF-1 concentrations, IGF-1-SDS and IGF-1:GH ration after adjusting for the confounding variabl